Abstract Details

Title Glial Fibrillary Acidic Protein (GFAP) Mutations, Age of Onset and Clinical Presentation in Alexander Disease

Topic Child Neurology/Developmental Neurobiology

Presentation(s) (-)

Poster/Presentation
Number 005

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Raphael Schiffmann, MD, FAAN (4D Molecular Therapeutics)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Adeline Vanderver, MD, FAAN (Children'S Hospital of Philadelphia)	An immediate family member of Dr. Vanderver has received personal compensation for serving as an employee of Maryland Physician Care. The institution of Dr. Vanderver has received research support from Takeda. The institution of Dr. Vanderver has received research support from Passage Bio. The institution of Dr. Vanderver has received research support from Homology. The institution of Dr. Vanderver has received research support from Eli Lilly. The institution of Dr. Vanderver has received research support from Myrtelle. The institution of Dr. Vanderver has received research support from SynaptixBio. The institution of Dr. Vanderver has received research support from PMD Foundation. The institution of Dr. Vanderver has received research support from Ionis. The institution of Dr. Vanderver has received research support from ISD . The institution of Dr. Vanderver has received research support from Boehringer-Ingelheim. The institution of Dr. Vanderver has received research support from Biogen. The institution of Dr. Vanderver has received research support from Sana. The institution of Dr. Vanderver has received research support from Affinia. The institution of Dr. Vanderver has received research support from BridgeBio. The institution of Dr. Vanderver has received research support from Orchard. The institution of Dr. Vanderver has received research support from Minoryx. The institution of Dr. Vanderver has received research support from Forge Biologics. The institution of Dr. Vanderver has received research support from Vigil. Dr. Vanderver has received intellectual property interests from a discovery or technology relating to health care. Dr. Vanderver has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file